Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC)
Crossref DOI link: https://doi.org/10.1007/s00520-015-2738-1
Published Online: 2015-05-05
Published Print: 2015-11
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Rapoport, Bernardo
Chua, Daniel
Poma, Allen
Arora, Sujata
Wang, Yan
Fein, Luis Enrique
Text and Data Mining valid from 2015-05-05